Clinical Trial Update: A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

AK112 is being studied in a Phase 1/Phase 2 trial for advanced hepatocellular carcinoma and is currently recruiting. The study is sponsored by Akeso.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK112

Snippet

Sponsor: Akeso | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: RECRUITING